List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 207 studies with search of: ( "june 01, 2009" : MAX ) [FIRST-RECEIVED-DATE] AND (lymphoma OR CLL [CONDITION ]) AND NOT myeloma [CONDITION]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions: Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
2 Not yet recruiting Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ofatumumab
3 Recruiting Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
4 Not yet recruiting Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
5 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
Intervention:
6 Active, not recruiting Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
Conditions: Immunocytoma/Morbus Waldenström;   B-Cell Non-Hodgkin's Lymphoma;   B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Cyclophosphamide, Pentostatin, Rituximab
7 Not yet recruiting Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Intervention: Drug: Lenalidomide, Rituximab, and Cyclophosphamide
8 Recruiting Asparaginase-Erwinia in Treating Patients With Acute Lymphoblastic Leukemia, T- Cell Lymphoma, or B-Cell Lymphoma Who Are Allergic to Asparaginase or Pegaspargase
Conditions: Leukemia;   Lymphoma;   Lymphoproliferative Disorder
Intervention: Drug: asparaginase-Erwinia
9 Not yet recruiting Bortezomib and Romidepsin in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: bortezomib;   Drug: romidepsin;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Recruiting Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Lenalidomide
11 Recruiting Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: vorinostat
12 Recruiting Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: cladribine;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
13 Recruiting Trial of Nonmyeloablative Conditioning With Fludarabine, Cyclophosphamide, and Total Body Irradiation Followed by Human Leukocyte Antigen (HLA)-Haploidentical or HLA-Identical Bone Marrow Transplantation, High-Dose Cyclophosphamide, and Rituximab for Patients With B-Cell Lymphoma
Conditions: Lymphoma;   B-Cell Lymphoma;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Bone marrow transplantation
14 Recruiting Quality of Life in Younger Leukemia and Lymphoma Survivors
Conditions: Anxiety Disorder;   Cancer Survivor;   Fatigue;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Adults;   Lymphoma;   Lymphoproliferative Disorder;   Pain;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer
Interventions: Behavioral: telephone-based intervention;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
15 Recruiting Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Drug: valproic acid;   Genetic: western blotting;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Completed Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
Conditions: Non-Hodgkin Lymphomas;   Follicular Lymphomas;   Immunocytomas;   Lymphocytic Lymphomas;   Marginal Zone Lymphomas
Interventions: Drug: Bendamustine;   Drug: Standard chemotherapy CHOP + Ritiximab
17 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
18 Enrolling by invitation Study of Tissue Samples From Patients With Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Interventions: Genetic: RNA analysis;   Genetic: gene mapping;   Genetic: microarray analysis;   Genetic: nucleic acid sequencing;   Genetic: polyacrylamide gel electrophoresis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: mass spectrometry
19 Not yet recruiting Autologous CD19-specific T Cells Infusion
Conditions: Lymphoma;   B-Cell Lymphoma
Interventions: Procedure: Leukapheresis;   Procedure: Stem Cell Transplant;   Procedure: CD19-specific T Cell Infusion;   Drug: IL-2;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Rituximab
20 Recruiting Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Lymphoma;   Precancerous/Nonmalignant Condition
Interventions: Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services